Posts

Madrigal Extends MASH Pipeline with $1B Arrowhead Deal for J&J-Rejected Asset

on

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

on

Madrigal Pharmaceuticals Secures $4.4B Deal for Six Preclinical siRNA Programs Targeting MASH from Ribo Life Science

on

Recent Biotech News: Altimmune's Pemvidutide Advances in MASH, Emerging China Obesity Players, and Ipsen Phase 2 Setback

on

Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites

on

PathAI’s AIM-MASH AI Assist Receives Historic FDA Qualification for MASH Clinical Trials

on

Behind-the-Scenes Details of 89bio's $2.4B Deal with Roche

on

Roche Acquires 89bio with $2.4 Billion Buyout to Enter FGF21 MASH Therapeutics Space

on

FDA Considers Noninvasive Endpoint for MASH Trials, Boosts Biotech Shares

on

FDA Grants Wegovy 3rd Indication: First GLP-1 Approved for MASH with Moderate-to-Advanced Liver Scarring

on

Madrigal Pharmaceuticals Inks up to $2B Deal with CSPC for Preclinical Oral GLP-1, Plans Combination with Rezdiffra for MASH

on

Altimmune's Incretin Misses Fibrosis Improvement Endpoints in MASH Trial

on

GSK Acquires Phase III-Ready Liver Drug Efimosfermin for Up to $2B to Enter MASH Arena

on

Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships

on

Inventiva Slashes Workforce and Pipeline to Focus on MASH Drug Lanifibranor

on

Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies

on

Akero Therapeutics Stock Skyrockets as Phase 2b MASH Trial Yields Groundbreaking Results

on